Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Methyltransferase MGMT upregulation drives metastasis by activating epithelial-mesenchymal transition in KRAS mutant colon cancer.

Cell death & disease - 16 May 2026

Liu Gaixia, Zhang Jiaqi, Li Qixin, Xue Xinzhu, Guo Xiaolong, Han Jing, Wang Guanghui, Shi Feiyu, Wang Kexuan, Ding Yi, Wu Hong, Hu Chenhao, She Junjun, Chen Yinnan

Abstract excerpt

Kirsten rat sarcoma (KRAS)-mutant colorectal cancer (CRC) is characterized by aggressive metastatic progression and profound therapeutic resistance. While direct inhibitors have emerged recently, their clinical application is often limited by rapid adaptive resistance, highlighting the urgent need to explore new therapeutic targets. Here, we identify O6-methylguanine-DNA methyltransferase (MGMT), a classical DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colonic Neoplasms
Share to DNA Modification Methylases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Repair Enzymes

Share to Epithelial-Mesenchymal Transition

Share to Histones

Share to Liver Neoplasms

Share to Neoplasm Metastasis

Share to Twist-Related Protein 1

Source

Open in PubMed Open full text

Identifiers

PMID: 42143085
DOI: 10.1038/s41419-026-08858-z
PMCID: PMC13346676

Genes

MGMT
KRAS
EGFR
TWIST1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Methyltransferase MGMT upregulation drives metastasis by activating epithelial-mesenchymal transition in KRAS mutant colon cancer.PMID 42143085Read ↗

Targeting mesenchymal-epithelial transition factor signaling in cancer: from genetic alterations to clinical advances and future prospects.Semantic proximity Read ↗

Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer.Semantic proximity Read ↗

KRAS inhibitors may prevent colorectal cancer metachronous metastasis by suppressing TGF‑β mediated epithelial‑mesenchymal transition.Semantic proximity Read ↗

Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression.Semantic proximity Read ↗

Clinicopathological significance and potential drug target of O6-methylguanine-DNA methyltransferase in colorectal cancer: a meta-analysis.Semantic proximity Read ↗

Correlation of KMT2 family mutations with molecular characteristics and prognosis in colorectal cancer.Semantic proximity Read ↗

Oncogenic Kras drives invasion and maintains metastases in colorectal cancer.Semantic proximity Read ↗

Genetic and epigenetic landscape of O6-methylguanine-DNA methyltransferase (MGMT): implications for DNA repair and cancer therapeuticsSemantic proximity Read ↗

Multimodal tumor suppression by METTL3 gene knockdown in melanoma and colon cancer cellsSemantic proximity Read ↗

Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.Semantic proximity Read ↗

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.Semantic proximity Read ↗

Pro-Oncogenic c-Met/EGFR, Biomarker Signatures of the Tumor Microenvironment are Clinical and Therapy Response Prognosticators in Colorectal Cancer, and Therapeutic Targets of 3-Phenyl-2H-benzo[e][1,3]-Oxazine-2,4(3H)-Dione DerivativesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.